Newsfeeds Archive - Page 2 of 7

2 minute read

LIXTE, Netherlands Cancer Institute, And Oncode Institute To Expand Collaboration

October 16, 8:49 AM

Extension Agreement Follows Successful Two-Year Collaboration in Colon CancerPASADENA, CA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) announced that it has signed an

LIXT

2 minute read

Lixte Biotechnology Holdings Announces The Passing Of Its Founder And Executive Chairman, John S. Kovach

By Benzinga Newsdesk

October 9, 8:38 AM

LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, today announced the passing of its

LIXT

2 minute read

Kirkland’s And 2 Other Stocks Under $3 Insiders Are Buying

By Lisa Levin

October 6, 8:59 AM

The Dow Jones closed lower by around 10 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

KIRK

2 minute read

Clearside Biomedical And 3 Other Stocks Under $3 Insiders Are Buying

By Lisa Levin

October 5, 9:07 AM

The Dow Jones closed higher by over 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

CLSD

2 minute read

LIXTE Appoints Bas Van Der Baan As President And Chief Executive Officer, Effective September 26, 2023

By Benzinga Newsdesk

September 26, 8:41 AM

LIXT

2 minute read

LIXTE Biotechnology Announces A Supported Collaborative Trial To Study LIXTE’s First-In-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, In Clear-Cell Ovarian Cancer

By Benzinga Newsdesk

September 20, 8:31 AM

The Phase 1b Clinical Trial Focuses on Assessing the Safety and Efficacy of the Two-Drug Combination in a Cancer Associated with Longer Survival to Immunotherapy When Genetically Deficient in PP2A PASADENA, CA,

LIXT

12 minute read

Options

Stocks That Hit 52-Week Lows On Monday

By Benzinga Insights

September 11, 1:38 PM

Monday's session saw 175 companies set new 52-week lows.

11 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

August 9, 12:27 PM

On Wednesday, 155 companies set new 52-week lows.

ABVC

5 minute read

Options

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

July 28, 12:36 PM

Friday's session saw 59 companies set new 52-week lows.

AADI

4 minute read

Why Willis Towers Watson Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session

By Lisa Levin

July 27, 12:53 PM

Gainers Femasys Inc. (NASDAQ: FEMY) gained 54% to $0.55. Femasys reported a notice of allowance for new U.S. patent application covering use of FemBloc for female permanent birth control.

ABVC